Clinical trial
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT00291694 · Carol Fabian, MD, Other · Completed
Key facts
| NCT number | NCT00291694 |
|---|---|
| Title | Protocol for Women at Increased Risk of Developing Breast Cancer |
| Official title | A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo |
| Lead sponsor | Carol Fabian, MD, Other |
| Collaborators | Susan G. Komen Breast Cancer Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | celecoxib, placebo |
| Enrollment | 72 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Feb 14, 2006 |
| Last update posted | Nov 7, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: